116 results on '"Verhaar HJ"'
Search Results
2. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial.
- Author
-
Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT, Emmelot-Vonk, Marielle H, Verhaar, Harald J J, Nakhai Pour, Hamid R, Aleman, André, Lock, Tycho M T W, Bosch, J L H Ruud, Grobbee, Diederick E, and van der Schouw, Yvonne T
- Abstract
Context: Serum testosterone levels decline significantly with aging. Testosterone supplementation to older men might beneficially affect the aging processes.Objective: To investigate the effect of testosterone supplementation on functional mobility, cognitive function, bone mineral density, body composition, plasma lipids, quality of life, and safety parameters in older men with low normal testosterone levels.Design, Setting, and Participants: Double-blind, randomized, placebo-controlled trial of 237 healthy men between the ages of 60 and 80 years with a testosterone level lower than 13.7 nmol/L conducted from January 2004 to April 2005 at a university medical center in the Netherlands.Intervention: Participants were randomly assigned to receive 80 mg of testosterone undecenoate or a matching placebo twice daily for 6 months.Main Outcome Measures: Functional mobility (Stanford Health Assessment Questionnaire, timed get up and go test, isometric handgrip strength, isometric leg extensor strength), cognitive function (8 different cognitive instruments), bone mineral density of the hip and lumbar spine (dual-energy x-ray absorptiometry scanning), body composition (total body dual-energy x-ray absorptiometry and abdominal ultrasound of fat mass), metabolic risk factors (fasting plasma lipids, glucose, and insulin), quality of life (Short-Form Health 36 Survey and the Questions on Life Satisfaction Modules), and safety parameters (serum prostate-specific antigen level, ultrasonographic prostate volume, International Prostate Symptom score, serum levels of creatinine, aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase, hemoglobin, and hematocrit).Results: A total of 207 men completed the study. During the study, lean body mass increased and fat mass decreased in the testosterone group compared with the placebo group but these factors were not accompanied by an increase of functional mobility or muscle strength. Cognitive function and bone mineral density did not change. Insulin sensitivity improved but high-density lipoprotein cholesterol decreased; by the end of the study, 47.8% in the testosterone group vs 35.5% in the placebo group had the metabolic syndrome (P = .07). Quality-of-life measures were no different except for one hormone-related quality-of-life measure that improved. No negative effects on prostate safety were detected.Conclusion: Testosterone supplementation during 6 months to older men with a low normal testosterone concentration did not affect functional status or cognition but increased lean body mass and had mixed metabolic effects.Trial Registration: isrctn.org Identifier: ISRCTN23688581. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
3. VERTOS II: Percutaneous vertebroplasty versus conservative therapy in patients with painful osteoporotic vertebral compression fractures; rationale, objectives and design of a multicenter randomized controlled trial
- Author
-
van der Graaf Y, Buskens E, Schoemaker MC, Tielbeek AV, Jansen FH, Blonk MC, Juttmann JR, Lampmann LEH, Verhaar HJJ, Klazen CAH, Janssens X, Fransen H, van Everdingen KJ, Muller AF, Mali WPThM, and Lohle PNM
- Subjects
Medicine (General) ,R5-920 - Abstract
Abstract Background The standard care in patients with a painful osteoporotic vertebral compression fracture (VCF) is conservative therapy. Percutaneous vertebroplasty (PV), a minimally invasive technique, is gaining popularity as a new treatment option. Many prospective and retrospective studies have reported on the effectiveness and safety of PV, but no large randomized controlled trial (RCT) has been published. Objective To estimate cost-effectiveness of PV compared to conservative therapy in terms of: pain reduction, quality of life, complications, secondary fractures and mortality. Materials and methods The VERTOS II study is designed as a prospective, multicenter RCT. Patients with a painful VCF with bone edema on MR imaging, local back pain for 6 weeks or less, osteopenia and aged 50 years or older, after obtaining informed consent are included and randomized for PV or conservative therapy. In total 200 patients will be enrolled. Follow-up is at regular intervals during a 1-year period with standard questionnaires, addressing: clinical symptoms, pain medication, Visual Analogue Scale (VAS) score, quality of life and cost-effectiveness. Secondary fractures, necessary additional therapies and complications are recorded. Conclusion The VERTOS II study is the first methodologically sound RCT designed to assess the cost-effectiveness of PV compared to conservative therapy in patients with an acute osteoporotic VCF. Trial registration http://www.clinicaltrials.gov, NCT00232466
- Published
- 2007
- Full Text
- View/download PDF
4. Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women >/= 70 years: study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial.
- Author
-
Jacobsen DE, Samson MM, Schouw YT, Grobbee DE, Verhaar HJ, Jacobsen, Didy E, Samson, Monique M, van der Schouw, Yvonne T, Grobbee, Diederick E, and Verhaar, Harald J J
- Abstract
Background: Postmenopausal women are prone to develop functional disabilities as a result of reduction in muscle strength and muscle mass caused by diminished levels of female sex hormones. While hormone replacement therapy may counteract these changes, conventional hormone replacement therapy is associated with potential harmful effects, such as an increased risk of breast cancer, and its prescription is not recommended. For this reason newer alternative drugs, such as tibolone, a synthetic steroid with estrogenic, progestogenic and androgenic activity, and raloxifene, a selective estrogen receptor modulator, may be more appropriate. This trial investigates the effect of tibolone and raloxifene on muscle strength.Methods: We recruited 318 elderly women in our single-center randomized, double-blind, double-dummy, placebo-controlled trial. Participants were randomized to tibolone 1.25 mg (Org OD 14, Organon NV, the Netherlands) plus placebo, raloxifene 60 mg (Evista(R), Eli Lilly, United States) plus placebo or two placebo tablets daily for 24 months.The primary aim is to determine if there is a difference between tibolone and placebo or if there is a difference between raloxifene and placebo. Primary endpoints are muscle strength and bone mineral density. The secondary endpoints are postural balance, body composition, cognitive function, anxiety, mood and quality of life. The secondary aim is to determine if there is a difference between tibolone and raloxifene. The measure of effect is the change from the baseline visit to the visits after 3 months, 6 months, 12 months, and 24 months. A follow-up measurement is planned at 30 months to determine whether any effects are sustained after cessation of the study. By December 2007 the blind will be broken and the data analyzed.Trial Registration Number: NTR: 1232. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
5. Determinants of vitamin D status in healthy men and women aged 40-80 years.
- Author
-
Janssen HC, Emmelot-Vonk MH, Verhaar HJ, van der Schouw YT, Janssen, H C J P, Emmelot-Vonk, M H, Verhaar, H J J, and van der Schouw, Y T
- Abstract
Objectives: To determine the contribution of life style and health related factors on vitamin D status in middle-aged and older men and women.Study Design: A cross-sectional single-center study in 400 male subjects (40-80 years) and 402 postmenopausal female subjects (56-73 years), conducted in a University Medical Center in the central part of the Netherlands (52 degrees northern latitude).Main Outcome Measures: Medical history, vitamin D, calcium and alcohol intake, physical activity, Body Mass Index, Blood pressure, smoking, total fat body mass and total lean body mass were measured using DEXA. Laboratory analysis included 25-hydroxyvitamin D (25OHD) and sex hormones.Results: Thirty-six percent of men and 51% of women had 25OHD less than 50 nmol/L. In summertime men had significant higher 25OHD as compared to women (81.5 vs 53.3 nmol/L, P=.000) but this difference disappeared come winter. In a saturated model, male gender (B=.16, P=.008), and season (summer vs winter B=.30, P=.000) remained statistically significant. In men, physical activity and season explained 21% of the variance. In women, household physical activity (B=.13, P=.03), sport physical activity (B=.02, P=.02) and estradiol (B=-.003, P=.048) remained in the model,.Conclusion: In healthy middle-aged and older men and postmenopausal women, male gender and season were important predictors of vitamin D status. In men, physically activity and season, explained 21% of the variance in vitamin D status. In women, physical activity and estradiol explained 9.3% of the variance in vitamin D. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
6. Etidronate for Prevention of Ectopic Mineralization in Patients With Pseudoxanthoma Elasticum.
- Author
-
Kranenburg G, de Jong PA, Bartstra JW, Lagerweij SJ, Lam MG, Ossewaarde-van Norel J, Risseeuw S, van Leeuwen R, Imhof SM, Verhaar HJ, de Vries JJ, Slart RHJA, Luurtsema G, den Harder AM, Visseren FLJ, Mali WP, and Spiering W
- Subjects
- Aged, Bone Density drug effects, Bone Density Conservation Agents administration & dosage, Bone Density Conservation Agents adverse effects, Bone Density Conservation Agents pharmacokinetics, Calcium blood, Calcium metabolism, Drug Monitoring methods, Female, Femur diagnostic imaging, Humans, Male, Middle Aged, Phosphates blood, Positron-Emission Tomography methods, Tomography, X-Ray Computed methods, Treatment Outcome, Etidronic Acid administration & dosage, Etidronic Acid adverse effects, Etidronic Acid pharmacokinetics, Peripheral Arterial Disease blood, Peripheral Arterial Disease diagnosis, Peripheral Arterial Disease etiology, Peripheral Arterial Disease prevention & control, Pseudoxanthoma Elasticum complications, Pseudoxanthoma Elasticum diagnosis, Pseudoxanthoma Elasticum drug therapy, Pseudoxanthoma Elasticum physiopathology, Vascular Calcification diagnosis, Vascular Calcification drug therapy, Vascular Calcification etiology
- Abstract
Background: In pseudoxanthoma elasticum (PXE), low pyrophosphate levels may cause ectopic mineralization, leading to skin changes, visual impairment, and peripheral arterial disease., Objectives: The authors hypothesized that etidronate, a pyrophosphate analog, might reduce ectopic mineralization in PXE., Methods: In the Treatment of Ectopic Mineralization in Pseudoxanthoma Elasticum trial, adults with PXE and leg arterial calcifications (n = 74) were randomly assigned to etidronate or placebo (cyclical 20 mg/kg for 2 weeks every 12 weeks). The primary outcome was ectopic mineralization, quantified with
18 fluoride positron emission tomography scans as femoral arterial wall target-to-background ratios (TBRfemoral ). Secondary outcomes were computed tomography arterial calcification and ophthalmological changes. Safety outcomes were bone density, serum calcium, and phosphate., Results: During 12 months of follow-up, the TBRfemoral increased 6% (interquartile range [IQR]: -12% to 25%) in the etidronate group and 7% (IQR: -9% to 32%) in the placebo group (p = 0.465). Arterial calcification decreased 4% (IQR: -11% to 7%) in the etidronate group and increased 8% (IQR: -1% to 20%) in the placebo group (p = 0.001). Etidronate treatment was associated with significantly fewer subretinal neovascularization events (1 vs. 9, p = 0.007). Bone density decreased 4% ± 12% in the etidronate group and 6% ± 9% in the placebo group (p = 0.374). Hypocalcemia (<2.20 mmol/l) occurred in 3 versus 1 patient (8.1% vs. 2.7%, p = 0.304). Eighteen patients (48.6%) treated with etidronate, compared with 0 patients treated with placebo (p < 0.001), experienced hyperphosphatemia (>1.5 mmol/l) and recovered spontaneously., Conclusions: In patients with PXE, etidronate reduced arterial calcification and subretinal neovascularization events but did not lower femoral18 fluoride sodium positron emission tomography activity compared with placebo, without important safety issues. (Treatment of Ectopic Mineralization in Pseudoxanthoma elasticum; NTR5180)., (Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
7. Links between Atherosclerosis and Osteoporosis in Middle Aged and Elderly Men.
- Author
-
van den Bos F, Emmelot-Vonk MH, Verhaar HJ, and van der Schouw YT
- Subjects
- Absorptiometry, Photon, Aged, Aorta physiology, Atherosclerosis complications, Blood Flow Velocity physiology, Blood Glucose analysis, C-Reactive Protein analysis, Carotid Intima-Media Thickness, Humans, Insulin blood, Lipids blood, Male, Middle Aged, Osteoporosis complications, Pulse Wave Analysis, Ultrasonography, Atherosclerosis pathology, Bone Density physiology, Insulin Resistance physiology, Osteoporosis pathology
- Abstract
Background: Although the incidences of osteoporosis and atherosclerosis increase with age, there is growing evidence that the coincidental occurrence of both diseases may be independent of age. In general, studies in men are scarce and results are inconsistent., Objective: to investigate the relationship between atherosclerosis and bone mineral density, and the influence of insulin sensitivity and low grade inflammation on this relationship in 332 men without CVD., Methods: Aortic Pulse wave velocity (PWV), augmentation index (AIX) and measurements of carotid intima media thickness (CIMT) were assessed. BMD measurements were performed with dual-X-ray absorptiometry (DEXA), subcutaneous fat by ultrasonography. Serum concentrations of lipids, hsCRP, glucose and insulin were measured. Insulin sensitivity was calculated by use of the quantitative insulin sensitivity (QUICKI). We used multivariate linear regression models to examine the association of hsCRP, insulin sensitivity, PWV, Aix, CIMT with BMD., Results: A higher CIMT was significantly associated with higher BMD after multivariate adjustment (ß 99.7; p=0.02). Further adjustment for weight attenuated the estimates towards non-significant. No association was found between PWV or AIX and BMD. Lower insulin sensitivity was associated with higher BMD (ß -645.1; p<0.01). After adjustment for weight this association was no longer significant. A similar effect was seen for the association between hsCRP and BMD., Conclusion: In this population of healthy, non-obese, men without a history of cardiovascular disease the positively association between cardiovascular parameters and BMD was mainly explained by weight, suggesting that in this population weight plays a protective role in the development of osteoporosis., Competing Interests: Frederiek van den Bos – Reports no disclosures; Marielle Emmelot-Vonk – Reports no disclosures; Harald Verhaar – Reports no disclosure; Yvonne van der Schouw – Reports no disclosures
- Published
- 2018
- Full Text
- View/download PDF
8. Accuracy of bone mineral density quantification using dual-layer spectral detector CT: a phantom study.
- Author
-
van Hamersvelt RW, Schilham AMR, Engelke K, den Harder AM, de Keizer B, Verhaar HJ, Leiner T, de Jong PA, and Willemink MJ
- Subjects
- Absorptiometry, Photon, Humans, Osteoporosis diagnostic imaging, Bone Density, Phantoms, Imaging, Tomography, X-Ray Computed methods
- Abstract
Objectives: To investigate the accuracy of bone mineral density (BMD) quantification using dual-layer spectral detector CT (SDCT) at various scan protocols., Methods: Two validated anthropomorphic phantoms containing inserts of 50-200 mg/cm
3 calcium hydroxyapatite (HA) were scanned using a 64-slice SDCT scanner at various acquisition protocols (120 and 140 kVp, and 50, 100 and 200 mAs). Regions of interest (ROIs) were placed in each insert and mean attenuation profiles at monochromatic energy levels (90-200 keV) were constructed. These profiles were fitted to attenuation profiles of pure HA and water to calculate HA concentrations. For comparison, one phantom was scanned using dual energy X-ray absorptiometry (DXA)., Results: At both 120 and 140 kVp, excellent correlations (R = 0.97, P < 0.001) were found between true and measured HA concentrations. Mean error for all measurements at 120 kVp was -5.6 ± 5.7 mg/cm3 (-3.6 ± 3.2%) and at 140 kVp -2.4 ± 3.7 mg/cm3 (-0.8 ± 2.8%). Mean measurement errors were smaller than 6% for all acquisition protocols. Strong linear correlations (R2 ≥ 0.970, P < 0.001) with DXA were found., Conclusions: SDCT allows for accurate BMD quantification and potentially opens up the possibility for osteoporosis evaluation and opportunistic screening in patients undergoing SDCT for other clinical indications. However, patient studies are needed to extend and translate our findings., Key Points: • Dual-layer spectral detector CT allows for accurate bone mineral density quantification. • BMD measurements on SDCT are strongly linearly correlated to DXA. • SDCT, acquired for several indications, may allow for evaluation of osteoporosis. • This potentially opens up the possibility for opportunistic osteoporosis screening.- Published
- 2017
- Full Text
- View/download PDF
9. Bone density loss on computed tomography at 3-year follow-up in current compared to former male smokers.
- Author
-
Pompe E, Bartstra J, Verhaar HJ, de Koning HJ, van der Aalst CM, Oudkerk M, Vliegenthart R, Lammers JJ, de Jong PA, and Mohamed Hoesein FAA
- Subjects
- Absorptiometry, Photon methods, Aged, Bone Density physiology, Early Detection of Cancer methods, Follow-Up Studies, Humans, Lumbar Vertebrae, Lung Neoplasms diagnosis, Lung Neoplasms physiopathology, Male, Middle Aged, Osteoporosis etiology, Osteoporosis physiopathology, Osteoporotic Fractures diagnostic imaging, Osteoporotic Fractures etiology, Osteoporotic Fractures physiopathology, Tomography, X-Ray Computed methods, Osteoporosis diagnostic imaging, Smoking adverse effects
- Abstract
Objectives: Cigarette smoking negatively affects bone quality and increases fracture risk. Little is known on the effect of smoking cessation and computed tomography (CT)-derived bone mineral density (BMD) decline in the spine. We evaluated the association of current and former smoking with BMD decline after 3-year follow-up., Methods: Male current and former smokers participating in a lung cancer screening trial who underwent baseline and 3-year follow-up CT were included. BMD was measured by manual placement of a region of interest in the first lumbar vertebra and expressed in Hounsfield Unit (HU). Multiple linear regression analysis was used to evaluate the association between pack years smoked and smoking status with BMD decline., Results: 408 participants were included with median (25th-75th percentile) age of 59.4 (55.9-63.5) years. At the start of the study, 197 (48.3%) participants were current smokers and 211 (51.7%) were former smokers and had a similar amount of pack years. Current smokers had quit smoking for 6 (4-8) years prior to inclusion. There was no difference in BMD between current and former smokers at baseline (109±34 HU vs. 108±32 HU, p=0.96). At 3-year follow-up, current smokers had a mean BMD decline of -3±13 HU (p=0.001), while BMD in former smokers did not change as compared to baseline (1±13 HU, p=0.34). After adjustment for BMD at baseline and body mass index, current smoking was independently associated with BMD decline (-3.8 HU, p=0.003). Age, pack years, and the presence of a fracture at baseline did not associate with BMD decline., Conclusions: Current smokers showed a more rapid BMD decline over a 3-year period compared to former smokers. This information might be important to identify subjects at risk for osteoporosis and emphasizes the importance of smoking cessation in light of BMD decline., (Copyright © 2017 Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
10. Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis.
- Author
-
Kranenburg G, Bartstra JW, Weijmans M, de Jong PA, Mali WP, Verhaar HJ, Visseren FLJ, and Spiering W
- Subjects
- Arteries physiopathology, Calcinosis physiopathology, Cardiovascular System drug effects, Female, Humans, Male, Neoplasms complications, Neoplasms mortality, Osteoporosis complications, Osteoporosis mortality, Randomized Controlled Trials as Topic, Risk Factors, Cardiovascular Diseases prevention & control, Diphosphonates therapeutic use, Risk Reduction Behavior, Vascular Stiffness drug effects
- Abstract
Background and Aims: Bisphosphonates might be effective in reducing cardiovascular events due to their ability to reduce calcification in arterial walls. We aimed to investigate the effects of treatment with bisphosphonates on the prevention of atherosclerotic processes and cardiovascular disease., Methods: Pubmed, Embase and the Cochrane Library were systematically reviewed by two independent investigators for randomized controlled studies published up to January 2016, in which the effect of bisphosphonates on arterial wall disease, cardiovascular events, cardiovascular mortality or all-cause mortality were reported. There was no restriction for the type of population used in the trials. Random-effects models were used to calculate the pooled estimates., Results: 61 trials reporting the effects of bisphosphonates on the outcomes of interest were included. Bisphosphonates had beneficial effects on arterial wall disease regarding arterial calcification (pooled mean percentage difference of 2 trials -11.52 (95% CI -16.51 to -6.52, p < 0.01, I(2) 13%), but not on arterial stiffness (pooled mean percentage difference of 2 trials -2.82; 95% CI -10.71-5.07; p = 0.48, I(2) 59%). No effect of bisphosphonate treatment on cardiovascular events was found (pooled RR of 20 trials 1.03; 95% CI 0.91-1.17, I(2) 16%), while a lower risk for cardiovascular mortality was observed in patients treated with bisphosphonates (pooled RR of 10 trials 0.81; 95% CI 0.64-1.02; I(2) 0%) although not statistically significant. Patients treated with bisphosphonates had a reduced risk of all-cause mortality (pooled RR of 48 trials 0.90; 95% CI 0.84-0.98; I(2) 53%)., Conclusions: In this systematic review and meta-analysis it is shown that bisphosphonates reduce arterial wall calcification but have no effect on arterial stiffness or on cardiovascular events. Bisphosphonates tend to reduce the risk of cardiovascular mortality and reduce all-cause mortality in various patient groups, including osteoporosis and cancer patients., (Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
11. Mild chronic kidney disease is associated with cognitive function in patients presenting at a memory clinic.
- Author
-
Romijn MD, van Marum RJ, Emmelot-Vonk MH, Verhaar HJ, and Koek HL
- Subjects
- Aged, Aged, 80 and over, Creatinine blood, Cross-Sectional Studies, Female, Glomerular Filtration Rate, Humans, Logistic Models, Male, Middle Aged, Models, Biological, Netherlands epidemiology, Prevalence, Renal Insufficiency, Chronic physiopathology, Renal Insufficiency, Chronic psychology, Retrospective Studies, Cognition Disorders epidemiology, Renal Insufficiency, Chronic epidemiology
- Abstract
Objective: In dialysis-dependent and severe chronic kidney disease (CKD) patients, cognitive impairment is found in 16-29%. In community-dwelling population without dementia mixed results have been observed. We investigated the relationship between renal function and cognition in patients from a memory clinic., Methods: We performed a cross-sectional study of consecutive patients from a memory clinic between 2005 and 2009. Renal function was estimated with the Modification of Diet in Renal Diseases (MDRD) and Cockcroft-Gault (CG) formulas, and categorized into ordinal groups: reference ≥ 60 ml/min/1.73 m(2), mild CKD 45-59 ml/min/1.73 m(2) and moderate CKD <45 ml/min/1.73 m(2). Cognitive function was dichotomized (Mini-Mental State Examination (MMSE) ≥ 24 vs. <24). We performed multiple logistic regression analyses with adjustment for potential confounders., Results: The cohort comprised 581 patients (mean age 77 ± 10 years). With the MDRD, there were 74 (12%) cases with moderate CKD and 108 (18%) with mild CKD. With the CG, these prevalences were 144 (30%) and 130 (27%). In mild CKD patients, a significant relationship was found between cognitive function and CKD according to the MDRD-formula [adjusted OR 2.10; 95%CI 1.09-4.05]. In moderate CKD patients, no significant adjusted associations were found. In patients without dementia, significant adjusted associations were found between CKD and MMSE (MDRD: mild CKD [OR 5.09; 95%CI 1.17-22.14] and moderate CKD [OR 5.03; 95%CI 1.10-22.98]; CG: mild CKD [OR 6.16; 95%CI 1.17-32.50] and moderate CKD [OR 5.60; 95%CI 1.01-30.91])., Conclusion: This study showed a significant association between mild CKD and impaired cognitive function in patients from a memory clinic, especially in patients without dementia., (Copyright © 2014 John Wiley & Sons, Ltd.)
- Published
- 2015
- Full Text
- View/download PDF
12. Opportunistic screening for osteoporosis on routine computed tomography? An external validation study.
- Author
-
Buckens CF, Dijkhuis G, de Keizer B, Verhaar HJ, and de Jong PA
- Subjects
- Absorptiometry, Photon methods, Aged, Bone Density physiology, Early Diagnosis, Female, Humans, Male, Middle Aged, Multimodal Imaging methods, Osteoporosis physiopathology, Osteoporotic Fractures physiopathology, Retrospective Studies, Sensitivity and Specificity, Spinal Fractures physiopathology, Tomography, X-Ray Computed methods, Osteoporosis diagnostic imaging, Osteoporotic Fractures diagnostic imaging, Spinal Fractures diagnostic imaging
- Abstract
Objectives: Opportunistic screening for osteoporosis using computed tomography (CT) examinations that happen to visualise the spine can be used to identify patients with osteoporosis. We sought to verify the diagnostic performance of vertebral Hounsfield unit (HU) measurements on routine CT examinations for diagnosing osteoporosis in a separate, external population., Methods: Consecutive patients who underwent a CT examination of the chest or abdomen and had also received a dual-energy X-ray absorptiometry (DXA) test were retrospectively included. CTs were evaluated for vertebral fractures and vertebral attenuation (density) values were measured. Diagnostic performance measures and the area under the receiver operator characteristics curve (AUC) for diagnosing osteoporosis were calculated., Results: Three hundred and two patients with a mean age of 57.9 years were included, of which 82 (27%) had osteoporosis according to DXA and 65 (22%) had vertebral fractures. The diagnostic performance for vertebral HU measurements was modest, with a maximal AUC of 0.74 (0.68 - 0.80). At that optimal threshold the sensitivity was 62% (51 - 72%) and the specificity was 79% (74 - 84%)., Conclusions: We confirmed that simple trabecular vertebral density measurements on routine CT contain diagnostic information related to bone mineral density as measured by DXA, albeit with substantially lower diagnostic accuracy than previously reported., Key Points: • We externally validated the value of vertebral trabecular bone attenuation for osteoporosis • These diagnostic performance measures were, however, substantially lower than previously reported • This information might be useful when considering the implementation of opportunistic osteoporosis screening.
- Published
- 2015
- Full Text
- View/download PDF
13. Vertebral fractures on routine chest computed tomography: relation with arterial calcifications and future cardiovascular events.
- Author
-
Buckens CF, de Jong PA, Verkooijen HM, Verhaar HJ, Mali WP, and van der Graaf Y
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Netherlands epidemiology, Osteoporotic Fractures epidemiology, Predictive Value of Tests, Prevalence, Prognosis, Risk Factors, Severity of Illness Index, Spinal Fractures epidemiology, Time Factors, Vascular Calcification epidemiology, Osteoporotic Fractures diagnostic imaging, Spinal Fractures diagnostic imaging, Tomography, X-Ray Computed, Vascular Calcification diagnostic imaging
- Abstract
Osteoporosis and cardiovascular disease often coexist. Vertebral fractures incidentally imaged in the course of routine care might be able to contribute to the prediction of cardiovascular events. Following a case-cohort design, 5,679 patients undergoing chest CT were followed for a median duration of 4.4 years. Cases were defined as patients who subsequently developed a cardiovascular event (n = 493). The presence and severity of vertebral fractures, as well as aortic, coronary and valvular calcifications on CT were investigated. Cases were more likely to be male (69 vs 60 %) and older (66 vs 61 years old). Prevalent vertebral fractures conferred an elevated risk of cardiovascular events after adjustment for age and gender [hazard ratio (HR) of 1.28, 95 % confidence interval (CI) 1.07 to 1.54]. This effect remained moderate after correction for cardiovascular calcifications (HR 1.20, CI 0.99-1.44). However, in terms of discrimination, vertebral fractures did not have substantial incremental prognostic value after correction (C-index was 0.683 vs 0.682 for models with and without vertebral fractures respectively). Prevalent vertebral fractures on routine clinical chest CT are related to future cardiovascular events but do not have additional prognostic value to models that already include age, gender and cardiovascular calcifications.
- Published
- 2015
- Full Text
- View/download PDF
14. Intravenous contrast injection significantly affects bone mineral density measured on CT.
- Author
-
Pompe E, Willemink MJ, Dijkhuis GR, Verhaar HJ, Mohamed Hoesein FA, and de Jong PA
- Subjects
- Adult, Aged, Carcinoma, Renal Cell complications, Female, Humans, Injections, Intravenous, Kidney Neoplasms complications, Lumbar Vertebrae diagnostic imaging, Male, Middle Aged, Retrospective Studies, Urologic Neoplasms complications, Bone Density physiology, Contrast Media administration & dosage, Osteoporosis diagnostic imaging, Tomography, X-Ray Computed methods
- Abstract
Objective: The objective is to evaluate the effect of intravenous contrast media on bone mineral density (BMD) assessment by comparing unenhanced and contrast-enhanced computed tomography (CT) examinations performed for other indications., Methods: One hundred and fifty-two patients (99 without and 53 with malignant neoplasm) who underwent both unenhanced and two contrast-enhanced (arterial and portal venous phase) abdominal CT examinations in a single session between June 2011 and July 2013 were included. BMD was evaluated on the three examinations as CT-attenuation values in Hounsfield Units (HU) in the first lumbar vertebra (L1)., Results: CT-attenuation values were significantly higher in both contrast-enhanced phases, compared to the unenhanced phase (p < 0.01). In patients without malignancies, mean ± standard deviation (SD) HU-values increased from 128.8 ± 48.6 HU for the unenhanced phase to 142.3 ± 47.2 HU for the arterial phase and 147.0 ± 47.4 HU for the portal phase (p < 0.01). In patients with malignancies, HU-values increased from 112.1 ± 38.1 HU to 126.2 ± 38.4 HU and 130.1 ± 37.3 HU (p < 0.02), respectively. With different thresholds to define osteoporosis, measurements in the arterial and portal phase resulted in 7-25% false negatives., Conclusions: Our study showed that intravenous contrast injection substantially affects BMD-assessment on CT and taking this into account may improve routine assessment of low BMD in nonquantitative CT., Key Points: • Routine CT may gain a role in bone attenuation measurements for osteoporosis • Contrast media injection has substantial influence on CT-derived bone density • Contrast-enhanced CT leads to underestimation of osteoporosis compared to unenhanced CT • Adjusting for contrast injection phase may improve CT screening protocols for osteoporosis.
- Published
- 2015
- Full Text
- View/download PDF
15. Osteoporosis markers on low-dose lung cancer screening chest computed tomography scans predict all-cause mortality.
- Author
-
Buckens CF, van der Graaf Y, Verkooijen HM, Mali WP, Isgum I, Mol CP, Verhaar HJ, Vliegenthart R, Oudkerk M, van Aalst CM, de Koning HJ, and de Jong PA
- Subjects
- Absorptiometry, Photon, Aged, Biomarkers blood, Bone Density physiology, Early Detection of Cancer, Female, Humans, Lung Neoplasms mortality, Male, Middle Aged, Osteoporosis mortality, Osteoporotic Fractures mortality, Proportional Hazards Models, Smoking mortality, Tomography, X-Ray Computed adverse effects, Lung Neoplasms diagnostic imaging, Osteoporosis diagnostic imaging, Osteoporotic Fractures diagnostic imaging, Spinal Fractures diagnostic imaging
- Abstract
Objectives: Further survival benefits may be gained from low-dose chest computed tomography (CT) by assessing vertebral fractures and bone density. We sought to assess the association between CT-measured vertebral fractures and bone density with all-cause mortality in lung cancer screening participants., Methods: Following a case-cohort design, lung cancer screening trial participants (N = 3,673) who died (N = 196) during a median follow-up of 6 years (inter-quartile range: 5.7-6.3) were identified and added to a random sample of N = 383 from the trial. We assessed vertebral fractures using Genant's semiquantative method on sagittal reconstructions and measured bone density (Hounsfield Units (HU)) in vertebrae. Cox proportional hazards modelling was used to determine if vertebral fractures or bone density were independently predictive of mortality., Results: The prevalence of vertebral fractures was 35% (95% confidence interval 30-40%) among survivors and 51% (44-58%) amongst cases. After adjusting for age, gender, smoking status, pack years smoked, coronary and aortic calcium volume and pulmonary emphysema, the adjusted hazard ratio (HR) for vertebral fracture was 2.04 (1.43-2.92). For each 10 HU decline in trabecular bone density, the adjusted HR was 1.08 (1.02-1.15)., Conclusions: Vertebral fractures and bone density are independently associated with all-cause mortality., Key Points: • Lung cancer screening chest computed tomography contains additional, potentially useful information. • Vertebral fractures and bone density are independently predictive of mortality. • This finding has implications for screening and management decisions.
- Published
- 2015
- Full Text
- View/download PDF
16. Prevalent vertebral fractures on chest CT: higher risk for future hip fracture.
- Author
-
Buckens CF, de Jong PA, Mali WP, Verhaar HJ, van der Graaf Y, and Verkooijen HM
- Subjects
- Adult, Age Factors, Aged, Aged, 80 and over, Female, Follow-Up Studies, Hospitalization, Humans, Male, Middle Aged, Netherlands epidemiology, Prevalence, Retrospective Studies, Risk Factors, Sex Factors, Spine, Hip Fractures diagnostic imaging, Hip Fractures epidemiology, Hip Fractures etiology, Radiography, Thoracic, Spinal Fractures complications, Spinal Fractures diagnostic imaging, Spinal Fractures epidemiology, Tomography, X-Ray Computed
- Abstract
Subclinical or undiagnosed vertebral fractures on routine chest computed tomography (CT) may be useful for detecting patients at increased risk of future hip fractures who might benefit from preventive interventions. We investigated whether prevalent vertebral fractures on routine chest CT are associated with future hip fractures. From a source population of 5679 patients ≥40 years old undergoing chest CT in one of three Dutch hospitals between 2002 and 2005, patients hospitalized for hip fractures (n = 149) during a median follow-up of 4.4 years were identified. Following a case-cohort design, a random sample of 576 patients was drawn from the source population and added to the cases. In this group, the presence and severity of vertebral fractures was determined using semiquantitative vertebral fracture assessment and multivariate case-cohort appropriate Cox modeling. We found that cases were older (69 versus 63 years) and more often female (48% versus 38%) than the source population. Compared with those with no fracture, patients with any vertebral fracture had triple the risk of future hip fracture (age- and gender-adjusted hazard ratio [HR] = 3.1, 95% confidence interval [CI] 2.1-4.7). This HR rose to 3.8 (CI 2.6-5.6) if mild fractures were discounted. Future fracture risk increased significantly with increasing severity of vertebral fracture status: from mild (HR = 2.4, CI 1.5-3.7) and moderate (HR = 4.8, CI 2.5-9.2) to severe (HR = 6.7, CI 2.9-15.5). The same was true for having higher cumulative fracture grades: 1 to 3 (HR = 2.7, CI 1.8-4.1), 4 to 6 (HR = 4.8, CI 2.2-10.5), or ≥7 (HR = 11.2, CI 3.7-34.6). In conclusion, prevalent vertebral fractures on routine clinical chest CT are associated with future hip fracture risk., (© 2014 American Society for Bone and Mineral Research.)
- Published
- 2014
- Full Text
- View/download PDF
17. Optimizing fracture prevention: the fracture liaison service, an observational study.
- Author
-
Eekman DA, van Helden SH, Huisman AM, Verhaar HJ, Bultink IE, Geusens PP, Lips P, and Lems WF
- Subjects
- Absorptiometry, Photon methods, Aged, Bone Density drug effects, Female, Humans, Male, Mass Screening organization & administration, Medication Adherence, Middle Aged, Netherlands epidemiology, Osteoporosis diagnosis, Osteoporosis drug therapy, Osteoporosis epidemiology, Osteoporotic Fractures epidemiology, Osteoporotic Fractures physiopathology, Outpatient Clinics, Hospital, Bone Density Conservation Agents therapeutic use, Osteoporotic Fractures prevention & control, Preventive Health Services organization & administration
- Abstract
Unlabelled: The response rate to the invitation to the fracture liaison service and reasons for non-response were evaluated in 2,207 fragility fracture patients. Fifty-one percent responded; non-responders were most often not interested (38 %) or were hip fracture patients. After 1 year of treatment, 88 % was still persistent and 2 % had a new fracture., Introduction: To increase the percentage of elderly fracture patients undergoing a dual energy x-ray absorptiometry (DXA) measurement, and to investigate why some patients did not respond to invitation to our fracture liaison service (FLS)., Methods: In four Dutch hospitals, fracture patients ≥ 50 years were invited through a written or personal invitation at the surgical outpatient department, for a DXA measurement and visit to our FLS. Patients who did not respond were contacted by telephone. In patients diagnosed with osteoporosis, treatment was started. Patients were contacted every 3 months during 1 year to assess drug persistence and the occurrence of subsequent fractures., Results: Of the 2,207 patients who were invited, 50.6 % responded. Most frequent reasons for not responding included: not interested (38 %), already screened/under treatment for osteoporosis (15.7 %), physically unable to attend the clinic (11.5 %), and death (5.2 %). Hip fracture patients responded less frequently (29 %) while patients with a wrist (60 %) or ankle fracture (65.2 %) were more likely to visit the clinic. In 337 responding patients, osteoporosis was diagnosed and treatment was initiated. After 12 months of follow-up, 88 % of the patients were still persistent with anti-osteoporosis therapy and only 2 % suffered a subsequent clinical fracture., Conclusion: In elderly fracture patients, the use of a FLS leads to an increased response rate, a high persistence to drug treatment, and a low rate of subsequent clinical fractures. Additional programs for hip fracture patients are required, as these patients have a low response rate.
- Published
- 2014
- Full Text
- View/download PDF
18. The association between vitamin D and cognition: a systematic review.
- Author
-
van der Schaft J, Koek HL, Dijkstra E, Verhaar HJ, van der Schouw YT, and Emmelot-Vonk MH
- Subjects
- Animals, Cognition drug effects, Cognition Disorders diagnosis, Cognition Disorders psychology, Cross-Sectional Studies, Dietary Supplements, Humans, Vitamin D Deficiency diagnosis, Vitamin D Deficiency psychology, Cognition physiology, Cognition Disorders blood, Vitamin D administration & dosage, Vitamin D blood, Vitamin D Deficiency blood
- Abstract
Vitamin D insufficiency and deficiency are a major health care problem. The association between vitamin D levels and cognitive function is still under debate. We conducted a systematic review to assess the association between levels of vitamin D and cognition. Therefore, the databases of Embase and Pubmed were searched through June 2012 for observational studies relating vitamin D levels to cognition. Our initial search yielded 2182 articles. After applying exclusion criteria, there were 28 studies eligible for inclusion: 25 cross-sectional and 6 prospective studies (3 studies show cross-sectional as well as prospective data). The main finding of the 25 cross-sectional studies was a statistically significant worse outcome on one or more cognitive function tests or a higher frequency of dementia with lower vitamin D levels or intake in 18 out of 25 (72%) studies, whereas 7 (28%) studies failed to show an association. Four out of 6 (66.7%) prospective studies showed a higher risk of cognitive decline after a follow-up period of 4-7 years in participants with lower vitamin D levels at baseline. In conclusion, this review supports the hypothesis that hypovitaminosis D is associated with worse outcome on one or more cognitive function tests or a higher frequency of dementia in cross-sectional as well as prospective studies. Further studies should focus on the role of vitamin D supplementation in the prevention of cognitive decline in participants with low vitamin D levels., (Copyright © 2013 Elsevier B.V. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
19. Vitamin D and muscle function: is there a threshold in the relation?
- Author
-
Janssen HC, Emmelot-Vonk MH, Verhaar HJ, and van der Schouw YT
- Subjects
- Adult, Aged, Aged, 80 and over, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Netherlands, Postmenopause, Regression Analysis, Body Composition, Hand Strength, Muscle, Skeletal, Psychomotor Performance, Vitamin D blood
- Abstract
Objectives: First, to determine the association between serum 25 hydroxyvitamin D (25OHD) concentration and muscle mass, strength, and performance. Second, to explore if there is a threshold in the association., Design: Cross-sectional, single-center study., Setting: The central part of the Netherlands (52° Northern latitude)., Participants: A total of 802 independently living men and postmenopausal women 40 to 80 years of age., Measurements: Health-related and lifestyle factors, including physical activity, 25OHD concentration, lean mass, handgrip strength, knee extension strength, and physical performance were determined., Results: Overall, higher 25OHD level was significantly associated with higher lean mass (22.6 g per nmol/L, 95% CI 7.3-37.9), handgrip strength (0.020 kg per nmol/L, 95% CI 0.001-0.038), and physical performance (0.006 points per nmol/L, 95% CI 0.001-0.012), after adjustment for various confounders. This association was most pronounced below a 25OHD level of 60 nmol/L, with lean mass increase 79.6 g per nmol/L (95% CI 40.8-118.4, P < .01), handgrip strength 0.09 kg per nmol/L (95% CI 0.045-0.141, P < .01), and physical performance 0.02 points per nmol/L (95% CI 0.005-0.032, P < .01), and these significant associations attenuated to null above this threshold., Conclusion: In middle-aged men and (postmenopausal) women, a higher 25OHD level was significantly associated with higher lean mass, muscle strength, and performance. These associations were most pronounced below 60 nmol/L and absent above 60 nmol/L, indicating a ceiling effect., (Copyright © 2013 American Medical Directors Association, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
20. Bone mineral density and vitamin D status in Parkinson's disease patients.
- Author
-
van den Bos F, Speelman AD, van Nimwegen M, van der Schouw YT, Backx FJ, Bloem BR, Munneke M, and Verhaar HJ
- Subjects
- Absorptiometry, Photon methods, Aged, Biomarkers blood, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Osteoporosis blood, Osteoporosis diagnostic imaging, Osteoporosis epidemiology, Parkinson Disease diagnostic imaging, Parkinson Disease epidemiology, Risk Factors, Vitamin D Deficiency diagnostic imaging, Vitamin D Deficiency epidemiology, Bone Density physiology, Parkinson Disease blood, Vitamin D blood, Vitamin D Deficiency blood
- Abstract
Bone loss is more common in Parkinson's disease (PD) than in the general population. Several factors may be involved in the development of bone loss, including malnutrition, immobilization, low body mass index, decreased muscle strength, vitamin D deficiency and medication use. This study investigates the prevalence of osteoporosis and possible risk factors associated with bone loss in early stage PD. In 186 PD patients (Hoehn and Yahr stage 1-2.5, mean age 64.1 years, 71 % men) bone mineral density (BMD) measurements were performed with DEXA. T- and Z-scores were calculated. Univariate linear regression analysis was performed to identify variables that contributed to BMD. 25-OH-vitamin D status of PD patients was compared with 802 controls (mean age 63.3 years, 50 % men) using linear regression analysis. Osteoporosis (11.8 %) and osteopenia (41.4 %) were common in PD patients. Mean Z-score for the hip was 0.24 (SD 0.93), and for the lumbar spine 0.72 (SD 1.91). Female gender, low weight, and low 25-OH-vitamin D were significantly correlated with BMD of the hip and lumbar spine. PD patients had lower 25(OH)D serum levels than controls (B = -10, p = 0.000). More than half of the patients with early stage PD had an abnormal BMD. Female gender, low weight, and low vitamin D concentration were associated with bone loss. Furthermore, vitamin D concentrations were reduced in PD patients. These results underscore the importance of proactive screening for bone loss and vitamin D deficiency, even in early stages of PD.
- Published
- 2013
- Full Text
- View/download PDF
21. Parkinson's disease and osteoporosis.
- Author
-
van den Bos F, Speelman AD, Samson M, Munneke M, Bloem BR, and Verhaar HJ
- Subjects
- Age Factors, Aged, Bone Density, Bone Density Conservation Agents therapeutic use, Bone Remodeling, Bone and Bones drug effects, Bone and Bones pathology, Calcium therapeutic use, Dietary Supplements, Female, Humans, Male, Middle Aged, Osteoporosis drug therapy, Osteoporosis pathology, Osteoporosis physiopathology, Osteoporotic Fractures pathology, Osteoporotic Fractures physiopathology, Osteoporotic Fractures prevention & control, Parkinson Disease pathology, Parkinson Disease physiopathology, Parkinson Disease therapy, Risk Assessment, Risk Factors, Risk Reduction Behavior, Sex Factors, Treatment Outcome, Vitamin D therapeutic use, Vitamin D Deficiency complications, Accidental Falls, Bone and Bones physiopathology, Osteoporosis etiology, Osteoporotic Fractures etiology, Parkinson Disease complications
- Abstract
Background: patients with Parkinson's disease (PD) have a high risk of sustaining osteoporotic fractures as a result of falls and reduced bone mass., Objective: to summarise the underlying pathophysiological mechanisms of bone loss in PD by reviewing the available literature., Methods: a Medline search was performed for articles published between January 1975 and January 2011, using the keywords 'bone mineral density', 'bone loss', 'bone metabolism', 'osteoporosis', 'osteopenia', 'Parkinson's disease' and 'Parkinsonism'., Results: PD patients have a lower bone mineral density (BMD) than age-matched controls. Bone loss in PD is multifactorial, resulting from immobility, decreased muscle strength, and low body weight. Vitamin D deficiency is also important, not only because it reduces BMD, but also because cell function in the substantia nigra depends on vitamin D. Lastly, hyperhomocysteinaemia, an independent risk factor for osteoporosis, is common in PD, due to levodopa use, as well as vitamin B12 and folic acid deficiency. A few studies have demonstrated that treatment with bisphosphonates, vitamin D and calcium can increase BMD and reduce fractures in PD patients., Conclusion: bone loss in PD is multifactorial. It is clinically important because of the concomitant risk of fractures. Screening for osteoporosis should be considered more often, and therapeutic interventions should be initiated.
- Published
- 2013
- Full Text
- View/download PDF
22. WITHDRAWN: Determinants of vitamin D status in healthy men and women aged 40-80 years.
- Author
-
Janssen HC, Emmelot-Vonk MH, Verhaar HJ, and van der Schouw YT
- Abstract
This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy., (Copyright © 2012. Published by Elsevier Ireland Ltd.. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
23. The association of chronic kidney disease with brain lesions on MRI or CT: a systematic review.
- Author
-
Vogels SC, Emmelot-Vonk MH, Verhaar HJ, and Koek HL
- Subjects
- Atrophy, Brain diagnostic imaging, Brain Diseases blood, Brain Diseases pathology, Cerebral Infarction blood, Creatinine blood, Humans, Leukoencephalopathies etiology, Magnetic Resonance Imaging, Radiography, Renal Insufficiency, Chronic blood, Tomography, Emission-Computed, Brain pathology, Brain Diseases etiology, Cerebral Infarction etiology, Cognition Disorders etiology, Dementia etiology, Glomerular Filtration Rate, Renal Insufficiency, Chronic complications
- Abstract
Background and Purpose: This review reports on the association between chronic kidney disease (CKD) established with glomerular filtration rate (GFR) and brain lesions established with MRI or CT., Methods: Literature was searched combining synonyms of kidney function, brain lesions and terms for the definitions thereof, and MRI or CT. This resulted in 1507 articles, of which 20 were finally included., Results: Cross-sectional studies found an association between GFR and white matter lesions (WML) with 7 out of 11 associations significant (odds ratios (OR) GFR, continuous variable: 0.84-0.89 per 10 ml/min/1.73 m(2)). Most significant results were found in studies including subjects from the general population. GFR was associated with silent cerebral infarcts (SCI) with 9 out of 12 associations significant (OR GFR, continuous variable: 0.96-0.99 per ml/min/1.73 m(2)). Brain atrophy was reported significant 4 out of 5 associations (OR GFR, continuous variable: 0.64 per 10 ml/min/1.73 m(2)). Additionally, 2 follow up studies were included. One established that serum creatinine at baseline is a significant predictor of the presence of SCI; the other that the presence of SCI at baseline is a significant predictor of a decrease in GFR., Conclusion: The results from this review show that CKD is associated with brain lesions. These brain lesions include WML, SCI and brain atrophy. This finding is of clinical importance because these brain lesions are predictive of stroke, cognitive decline and dementia. Additional follow up studies should be performed to better understand the causative pathway and to establish whether screening and preventive programs are beneficial., (Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
24. Raloxifene and tibolone in elderly women: a randomized, double-blind, double-dummy, placebo-controlled trial.
- Author
-
Jacobsen DE, Melis RJ, Verhaar HJ, and Olde Rikkert MG
- Subjects
- Absorptiometry, Photon, Academic Medical Centers, Age Factors, Aged, Aged, 80 and over, Body Mass Index, Bone Density drug effects, Bone Density Conservation Agents administration & dosage, Bone Density Conservation Agents adverse effects, Confidence Intervals, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Drug Administration Schedule, Drug-Related Side Effects and Adverse Reactions, Estrogen Receptor Modulators administration & dosage, Estrogen Receptor Modulators adverse effects, Female, Follow-Up Studies, Humans, Middle Aged, Netherlands, Norpregnenes adverse effects, Patient Safety, Raloxifene Hydrochloride adverse effects, Reference Values, Risk Assessment, Severity of Illness Index, Treatment Outcome, Norpregnenes administration & dosage, Osteoporosis, Postmenopausal diagnosis, Osteoporosis, Postmenopausal drug therapy, Raloxifene Hydrochloride administration & dosage
- Abstract
Objectives: The authors' first aim was to study the effects of raloxifene and tibolone on body mass density, handgrip strength, and other secondary frailty components. The secondary aim was to compare the effects of raloxifene and tibolone and their safety in older women., Design/setting/participants: A randomized, double-blind, double- dummy, placebo-controlled trial conducted in an academic hospital in the Netherlands among 318 community living women aged >70 were randomized; 290 received the allocated intervention: 97 placebo, 101 raloxifene, and 92 tibolone., Interventions: Randomization was made to raloxifene 60 mg, tibolone 1.25 mg, or placebo. Assessments were performed at baseline and after 3, 6, 12, and 24 months. The study was conducted from July 2003 to January 2008. The tibolone group stopped earlier in February 2006, because of results of the Long-Term Intervention on Fractures with Tibolone study, suggesting an increased risk of cerebrovascular accident., Measurements: Primary endpoints were body mass density and handgrip strength. Secondary endpoints were muscle power and strength, mobility measures, body composition, verbal memory, mental processing speed, anxiety, mood, and quality of life., Results: Tibolone and raloxifene had similar body mass density-effect sizes (d = .24-.47), and had no effect on handgrip muscle strength. For the 15 words test the effect on direct recall of concrete and abstract words (d = .40 and d =.27, respectively) and on delayed recall of concrete words (d = .77) were significantly higher in the raloxifene group compared to placebo and to tibolone. In the raloxifene group the health status (EuroQol VAS (0-100) was improved 2.4 points [95% CI 0.5-4.2; P = .012] over 24 months., Conclusion: In women >70 years old, raloxifene and tibolone significantly and similarly increased body mass density but not muscle strength. Raloxifene had also positive effects on verbal memory and health status. New research with selective estrogen receptor modulators like raloxifene might be promising on frailty endpoints in elderly women., Trial Registration Number: Nederlands Trial Register: 1232., (Copyright © 2012 American Medical Directors Association, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
25. Therapeutic challenges in elderly patients with symptomatic hypercalcaemia caused by primary hyperparathyroidism.
- Author
-
Jacobs L, Samson MM, Verhaar HJ, and Koek HL
- Subjects
- Age Factors, Aged, Aged, 80 and over, Aging, Cinacalcet, Female, Humans, Hypercalcemia diagnosis, Hypercalcemia etiology, Hyperparathyroidism, Primary drug therapy, Hyperparathyroidism, Primary pathology, Calcimimetic Agents therapeutic use, Hypercalcemia drug therapy, Hyperparathyroidism, Primary complications, Naphthalenes therapeutic use
- Abstract
Background: Hypercalcaemia resulting from primary hyperparathyroidism (PHPT) can cause a wide range of symptoms, including cognitive disorders, psychiatric symptoms and muscle weakness. Parathyroid surgery is the only definite cure for PHPT. When surgery is contraindicated or patients decide against it, several non-surgical treatment options are available., Objective: To illustrate the treatment options of symptomatic hypercalcaemia caused by PHPT in the elderly and discuss these options in consideration of the available evidence., Design: Consecutive case series., Setting: University hospital., Patients: Four older patients aged 79-87 years with symptomatic hypercalcaemia resulting from PHPT., Results: Three patients had a parathyroid adenoma shown on a sestamibi scan. Normocalcaemia and resolution of symptoms was achieved by different treatment scenarios encompassing forced saline hydration, forced diuresis, intravenous pamidronate and cinacalcet, a calcimimetic drug. In one patient, no parathyroid abnormalities were revealed with imaging. Treatment with cinacalcet resulted in normocalcaemia and a strong improvement of symptoms., Conclusion: In clinical practice, different treatment scenarios are chosen for the treatment of elderly patients with symptomatic hypercalcaemia caused by PHPT. The introduction of cinacalcet offers a new treatment paradigm. We propose to apply cinacalcet preceding elective surgery as an alternative option to standard therapy or as maintenance dose when surgery is not possible.
- Published
- 2012
26. [The effectiveness of falls clinics in the Netherlands].
- Author
-
Emmelot-Vonk MH and Verhaar HJ
- Subjects
- Activities of Daily Living, Aged, Humans, Netherlands, Patient Selection, Risk Factors, Accidental Falls prevention & control, Geriatric Assessment methods, Program Evaluation, Risk Assessment methods
- Abstract
Recently, two articles are published about the effectiveness of a multifactorial fall prevention programme performed by two falls clinics in the Netherlands. Both studies have shown negative results. The question is if those two studies are representative for the real situation in most falls clinics in the Netherlands. Two important differences are the selection of the patients and the completion of the fall prevention program. It is important to select the patients with the highest fall risk (> or = 2 falls/year and/or > or = 4 fall risk factors) and to provide an active and direct management of the identified fall risk factors to improve the effectiveness of falls clinics.
- Published
- 2011
- Full Text
- View/download PDF
27. Low testosterone concentrations and the symptoms of testosterone deficiency according to the Androgen Deficiency in Ageing Males (ADAM) and Ageing Males' Symptoms rating scale (AMS) questionnaires.
- Author
-
Emmelot-Vonk MH, Verhaar HJ, Nakhai-Pour HR, Grobbee DE, and van der Schouw YT
- Subjects
- Aged, Aged, 80 and over, Humans, Male, Middle Aged, Surveys and Questionnaires, Androgens deficiency, Testosterone blood, Testosterone deficiency
- Abstract
Objective: First, to assess the association between the concentration of serum testosterone and the symptoms of testosterone deficiency according to two screening questionnaires. Second, to investigate the effects in elderly men with a low-normal testosterone concentration of testosterone supplementation over a period of 6 months on symptoms of testosterone deficiency according to the screening questionnaires., Design, Setting and Participants: A total of 587 men between 60 and 80 years of age with an eligible serum testosterone measurement and completion of the screening questionnaires were included in the study. Of these 587 men, 237 men with testosterone levels <13·7 nmol/l were included in a double-blind, randomized, placebo-controlled trial of testosterone supplementation., Intervention: One hundred and sixty milligrams per day of oral testosterone undecanoate or a matching placebo for 6 months., Measurements: The Androgen Deficiency in Ageing Males (ADAM) and the Ageing Males' Symptoms rating scale (AMS) questionnaires., Results: There was no significant association between the total testosterone concentration and the scores on the two questionnaires. However, age was significantly associated with the scores on the ADAM (OR 1·14, 95% CI 1·05-1·23) and the AMS (OR 1·03, 95% CI 1·01-1·08) questionnaire. After supplementation with testosterone, there were no effects on the scores on the two questionnaires in the testosterone group compared with the placebo group., Conclusion: The findings do not support the use of the ADAM or AMS questionnaire in the evaluation of late-onset hypogonadism in ageing men. Moreover, 6 months of oral testosterone supplementation had no significant effect on scores of the ADAM and AMS questionnaire in this group of elderly men with low-normal testosterone levels., (© 2011 Blackwell Publishing Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
28. Geriatric conditions in acutely hospitalized older patients: prevalence and one-year survival and functional decline.
- Author
-
Buurman BM, Hoogerduijn JG, de Haan RJ, Abu-Hanna A, Lagaay AM, Verhaar HJ, Schuurmans MJ, Levi M, and de Rooij SE
- Subjects
- Aged, Cohort Studies, Follow-Up Studies, Humans, In Vitro Techniques, Male, Patient Discharge statistics & numerical data, Prognosis, Prospective Studies, Survival Analysis, Geriatrics statistics & numerical data, Hospitalization statistics & numerical data, Prevalence
- Abstract
Background: To study the prevalence of eighteen geriatric conditions in older patients at admission, their reporting rate in discharge summaries and the impact of these conditions on mortality and functional decline one year after admission., Method: A prospective multicenter cohort study conducted between 2006 and 2008 in two tertiary university teaching hospitals and one regional teaching hospital in the Netherlands. Patients of 65 years and older, acutely admitted and hospitalized for at least 48 hours, were invited to participate. Eighteen geriatric conditions were assessed at hospital admission, and outcomes (mortality, functional decline) were assessed one year after admission., Results: 639 patients were included, with a mean age of 78 years. IADL impairment (83%), polypharmacy (61%), mobility difficulty (59%), high levels of primary caregiver burden (53%), and malnutrition (52%) were most prevalent. Except for polypharmacy and cognitive impairment, the reporting rate of the geriatric conditions in discharge summaries was less than 50%. One year after admission, 35% had died and 33% suffered from functional decline. A high Charlson comorbidity index score, presence of malnutrition, high fall risk, presence of delirium and premorbid IADL impairment were associated with mortality and overall poor outcome (mortality or functional decline). Obesity lowered the risk for mortality., Conclusion: Geriatric conditions were highly prevalent and associated with poor health outcomes after admission. Early recognition of these conditions in acutely hospitalized older patients and improving the handover to the general practitioner could lead to better health outcomes and reduce the burden of hospital admission for older patients.
- Published
- 2011
- Full Text
- View/download PDF
29. Vertebroplasty versus conservative treatment in acute osteoporotic vertebral compression fractures (Vertos II): an open-label randomised trial.
- Author
-
Klazen CA, Lohle PN, de Vries J, Jansen FH, Tielbeek AV, Blonk MC, Venmans A, van Rooij WJ, Schoemaker MC, Juttmann JR, Lo TH, Verhaar HJ, van der Graaf Y, van Everdingen KJ, Muller AF, Elgersma OE, Halkema DR, Fransen H, Janssens X, Buskens E, and Mali WP
- Subjects
- Aged, Aged, 80 and over, Belgium, Bone Cements economics, Cost-Benefit Analysis, Female, Fractures, Compression economics, Fractures, Compression etiology, Fractures, Compression surgery, Humans, Male, Middle Aged, Netherlands, Pain etiology, Pain Measurement, Prospective Studies, Quality-Adjusted Life Years, Spinal Fractures economics, Spinal Fractures etiology, Spinal Fractures surgery, Surveys and Questionnaires, Time Factors, Treatment Outcome, Bone Cements therapeutic use, Fractures, Compression therapy, Osteoporosis complications, Pain Management, Spinal Fractures therapy, Vertebroplasty economics
- Abstract
Background: Percutaneous vertebroplasty is increasingly used for treatment of pain in patients with osteoporotic vertebral compression fractures, but the efficacy, cost-effectiveness, and safety of the procedure remain uncertain. We aimed to clarify whether vertebroplasty has additional value compared with optimum pain treatment in patients with acute vertebral fractures., Methods: Patients were recruited to this open-label prospective randomised trial from the radiology departments of six hospitals in the Netherlands and Belgium. Patients were aged 50 years or older, had vertebral compression fractures on spine radiograph (minimum 15% height loss; level of fracture at Th5 or lower; bone oedema on MRI), with back pain for 6 weeks or less, and a visual analogue scale (VAS) score of 5 or more. Patients were randomly allocated to percutaneous vertebroplasty or conservative treatment by computer-generated randomisation codes with a block size of six. Masking was not possible for participants, physicians, and outcome assessors. The primary outcome was pain relief at 1 month and 1 year as measured by VAS score. Analysis was by intention to treat. This study is registered at ClinicalTrials.gov, number NCT00232466., Findings: Between Oct 1, 2005, and June 30, 2008, we identified 431 patients who were eligible for randomisation. 229 (53%) patients had spontaneous pain relief during assessment, and 202 patients with persistent pain were randomly allocated to treatment (101 vertebroplasty, 101 conservative treatment). Vertebroplasty resulted in greater pain relief than did conservative treatment; difference in mean VAS score between baseline and 1 month was -5·2 (95% CI -5·88 to -4·72) after vertebroplasty and -2·7 (-3·22 to -1·98) after conservative treatment, and between baseline and 1 year was -5·7 (-6·22 to -4·98) after vertebroplasty and -3·7 (-4·35 to -3·05) after conservative treatment. The difference between groups in reduction of mean VAS score from baseline was 2·6 (95% CI 1·74-3·37, p<0·0001) at 1 month and 2·0 (1·13-2·80, p<0·0001) at 1 year. No serious complications or adverse events were reported., Interpretation: In a subgroup of patients with acute osteoporotic vertebral compression fractures and persistent pain, percutaneous vertebroplasty is effective and safe. Pain relief after vertebroplasty is immediate, is sustained for at least a year, and is significantly greater than that achieved with conservative treatment, at an acceptable cost., Funding: ZonMw; COOK Medical., (Copyright © 2010 Elsevier Ltd. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
30. Percutaneous vertebroplasty and pulmonary cement embolism: results from VERTOS II.
- Author
-
Venmans A, Klazen CA, Lohle PN, van Rooij WJ, Verhaar HJ, de Vries J, and Mali WP
- Subjects
- Aged, Aged, 80 and over, Azygos Vein, Female, Follow-Up Studies, Fractures, Compression epidemiology, Fractures, Compression therapy, Humans, Incidence, Male, Middle Aged, Osteoporosis epidemiology, Pulmonary Embolism diagnostic imaging, Pulmonary Embolism epidemiology, Risk Factors, Spinal Fractures epidemiology, Tomography, Spiral Computed, Bone Cements adverse effects, Osteoporosis therapy, Pulmonary Embolism etiology, Spinal Fractures therapy, Vertebroplasty adverse effects, Vertebroplasty methods, Vertebroplasty statistics & numerical data
- Abstract
Background and Purpose: The reported incidence of PCE during PV varies, depending on the sensitivity of diagnostic tests used. To assess the true incidence of PCE, we performed native chest CT during follow-up in a large proportion of patients from the VERTOS II trial., Materials and Methods: VERTOS II is a prospective multicenter randomized controlled trial comparing PV with conservative therapy in 202 patients. After a mean follow-up of 22 months (median, 21 months; range, 6-42 months), 54 of 78 patients (69%) with 80 vertebrae treated with PV underwent native chest CT to detect possible PCE. The presence, location, number, and size of PCE were recorded. In addition, the presence of pulmonary parenchymal changes adjacent to PCE was noted. Possible risk factors for PCE, such as age, sex, number of treated vertebrae, cement volume per vertebra, and presence and location of perivertebral cement leakage, were evaluated., Results: PCE was detected in 14 of 54 patients (26% 95% CI, 16%-39%). All patients were asymptomatic. Cement emboli were small and randomly distributed in peripheral small vessels. There were no reactive pulmonary changes. Cement leakage in the azygos vein was the only risk factor for the occurrence of PCE (OR, 43; 95% CI, 5-396)., Conclusions: Small and clinically silent PCE occurred in a quarter of patients treated with PV. Cement leakage into the azygos vein was the only risk factor. With time, these small cement emboli remained inert, without inflammatory pulmonary response. Standard postprocedural CT or chest radiographs are not necessary.
- Published
- 2010
- Full Text
- View/download PDF
31. Clinical course of pain in acute osteoporotic vertebral compression fractures.
- Author
-
Klazen CA, Verhaar HJ, Lohle PN, Lampmann LE, Juttmann JR, Schoemaker MC, van Everdingen KJ, Muller AF, Mali WP, and de Vries J
- Subjects
- Acute Disease, Aged, Aged, 80 and over, Analgesics therapeutic use, Back Pain etiology, Chronic Disease, Disease Progression, Female, Follow-Up Studies, Fracture Healing, Fractures, Compression diagnostic imaging, Fractures, Compression etiology, Humans, Logistic Models, Male, Middle Aged, Netherlands, Orthopedic Procedures, Osteoporosis diagnostic imaging, Pain Measurement, Physical Therapy Modalities, Prospective Studies, Radiography, Risk Assessment, Risk Factors, Spinal Fractures diagnostic imaging, Spinal Fractures etiology, Surveys and Questionnaires, Time Factors, Treatment Outcome, Analgesia methods, Back Pain therapy, Fractures, Compression therapy, Osteoporosis complications, Spinal Fractures therapy
- Abstract
Purpose: The authors prospectively determined the natural course of pain in patients with conservatively treated acute osteoporotic vertebral compression fractures (VCF). In addition, the type of conservative therapy that these patients received was assessed., Materials and Methods: Patients older than 50 years, referred for spine radiography for acute back pain, were asked to complete a baseline clinical questionnaire. Patients with an acute VCF were followed up at 6 and 23 months with a questionnaire that included a Visual Analog Score (VAS) and type of pain medication and other conservative treatment. Significant pain relief was defined as a decrease in VAS of 50% or more., Results: Forty-nine patients (mean age, 78 years; range, 51-95) with acute VCF were followed up for almost 2 years. Significant pain relief was noted in 22 of 35 patients (63%) at 6 months and in 25 of 36 (69%) at 23 months. In patients with persisting pain at 23 months (mean VAS 6.4), some decrease in VAS was apparent at 6 months but not in the 6-23 months interval. No predictors for significant pain relief could be identified. Patients with significant pain relief used less pain medication and had less physical therapy., Conclusions: In most patients with an acute VCF, pain decreases significantly with conservative therapy, predominantly in the first 6 months. However, almost 2 years after an acute VCF, a third of patients still had severe pain necessitating pain medication and physical therapy in the majority. No predictors for transition from acute to chronic pain could be identified., (Copyright 2010 SIR. Published by Elsevier Inc. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
32. Percutaneous vertebroplasty is not a risk factor for new osteoporotic compression fractures: results from VERTOS II.
- Author
-
Klazen CA, Venmans A, de Vries J, van Rooij WJ, Jansen FH, Blonk MC, Lohle PN, Juttmann JR, Buskens E, van Everdingen KJ, Muller A, Fransen H, Elgersma OE, Mali WP, and Verhaar HJ
- Subjects
- Aged, Aged, 80 and over, Female, Follow-Up Studies, Fractures, Compression diagnostic imaging, Fractures, Compression epidemiology, Humans, Incidence, Kaplan-Meier Estimate, Male, Middle Aged, Osteoporosis diagnostic imaging, Osteoporosis epidemiology, Prospective Studies, Radiography, Recurrence, Risk Factors, Severity of Illness Index, Spinal Fractures diagnostic imaging, Spinal Fractures epidemiology, Vertebroplasty statistics & numerical data, Fractures, Compression therapy, Osteoporosis therapy, Spinal Fractures therapy, Vertebroplasty methods
- Abstract
Background and Purpose: PV is increasingly used as treatment for osteoporotic VCFs. However, controversy exists as to whether PV increases the risk for new VCFs during follow-up. The purpose of our research was to assess the incidence of new VCFs in patients with acute VCFs randomized to PV and conservative therapy., Materials and Methods: VERTOS II is a prospective multicenter randomized controlled trial comparing PV with conservative therapy in 202 patients. Incidence, distribution, and timing of new VCFs during follow-up were assessed from spine radiographs. In addition, further height loss during follow-up of treated VCFs was measured., Results: After a mean follow-up of 11.4 months (median, 12.0; range, 1-24 months), 18 new VCFs occurred in 15 of 91 patients after PV and 30 new VCFs in 21 of 85 patients after conservative therapy. This difference was not significant (P = .44). There was no higher fracture risk for adjacent-versus-distant vertebrae. Mean time to new VCF was 16.2 months after PV and 17.8 months after conservative treatment (logrank, P = .45). The baseline number of VCFs was the only risk factor for occurrence (OR, 1.43; 95% CI, 1.05-1.95) and number (P = .01) of new VCFs. After conservative therapy, further height loss of treated vertebrae occurred more frequently (35 of 85 versus 11 of 91 patients, P < .001) and was more severe (P < .001) than after PV., Conclusions: Incidence of new VCFs was not different after PV compared with conservative therapy after a mean of 11.4 months' follow-up. The only risk factor for new VCFs was the number of VCFs at baseline. PV contributed to preservation of stature by decreasing both the incidence and severity of further height loss in treated vertebrae.
- Published
- 2010
- Full Text
- View/download PDF
33. PTH analogues and osteoporotic fractures.
- Author
-
Verhaar HJ and Lems WF
- Subjects
- Amino Acid Sequence, Bone Density Conservation Agents adverse effects, Bone Density Conservation Agents pharmacokinetics, Female, Fractures, Bone etiology, Fractures, Bone metabolism, Fractures, Bone physiopathology, Humans, Male, Molecular Sequence Data, Osteoporosis complications, Osteoporosis metabolism, Osteoporosis physiopathology, Parathyroid Hormone adverse effects, Parathyroid Hormone analogs & derivatives, Parathyroid Hormone pharmacokinetics, Peptide Fragments adverse effects, Peptide Fragments pharmacokinetics, Treatment Outcome, Bone Density Conservation Agents therapeutic use, Bone Remodeling drug effects, Fractures, Bone prevention & control, Osteoporosis drug therapy, Parathyroid Hormone therapeutic use, Peptide Fragments therapeutic use
- Abstract
Importance of the Field: At present there are two parathyroid hormone (PTH) analogues (PTH 1 - 34 and PTH 1 - 84) registered for the treatment of established osteoporosis in postmenopausal women (PTH 1 - 34 and PTH 1 - 84) and in men (PTH 1 - 34 only) who are at increased risk of having a fracture., Areas Covered in This Review: The efficacy and safety of PTH 1 - 34 and PTH 1 - 84 in the management of osteoporosis is evaluated by reviewing published literature and presentations from scientific meetings through to 2010., What the Reader Will Gain: This review focuses on data on fracture risk reduction and safety endpoints of PTH analogues. The adverse reactions reported most are nausea, pain in the extremities, headache and dizziness., Take Home Message: Exogenous PTH analogues, given as daily subcutaneous injections, stimulate bone formation, increase bone mass and bone strength, and improve calcium balance. In postmenopausal women with osteoporosis, PTH analogues reduced the risk of vertebral (PTH 1 - 34 and PTH 1 - 84) and non-vertebral fractures (only PTH 1 - 34). In men and women with glucocorticosteroid-induced osteoporosis, PTH 1 - 34 reduced the risk of vertebral fractures. In general, PTH analogues are well tolerated with an acceptable safety profile: they can be used for the prevention and treatment of fractures in postmenopausal women with severe, established osteoporosis.
- Published
- 2010
- Full Text
- View/download PDF
34. Effects of probiotics on acquisition and spread of multiresistant enterococci.
- Author
-
de Regt MJ, Willems RJ, Hené RJ, Siersema PD, Verhaar HJ, Hopmans TE, and Bonten MJ
- Subjects
- Aged, Ampicillin Resistance, Enterococcus genetics, Enterococcus physiology, Female, Humans, Male, Middle Aged, Prospective Studies, Vancomycin Resistance, Drug Resistance, Multiple, Bacterial drug effects, Enterococcus drug effects, Probiotics pharmacology
- Abstract
Ampicillin-resistant Enterococcus faecium (ARE) and vancomycin-resistant E. faecium (VRE) are important nosocomial pathogens. We quantified effects of probiotics and antibiotics on intestinal acquisition of ARE colonization in patients hospitalized in two non-intensive care unit (non-ICU) wards with high ARE prevalence. In a prospective cohort study with crossover design, all patients with a length of stay of >48 h were offered a multispecies probiotic product twice daily until discharge (4.5 months, intervention period) or not (4.5 months, control period). Perianal ARE carriage was determined <48 h after admission, twice weekly, and <48 h before discharge. The first isolates were genotyped by multiple-locus variable-number tandem repeat analysis (MLVA). Risk factors for acquisition were determined by Cox proportional hazards modeling, with special emphasis on ecological postantibiotic effects and delays between actual acquisition and culture positivity. Of 530 patients included, 94 (18%) were ARE colonized on admission. Of the remaining 436 noncolonized patients, 92 acquired ARE colonization: 28 (25%) of 110 probiotic users and 64 (20%) of 326 control patients (chi(2) test, P = 0.325). In all, 661 ARE strains were isolated from 186 patients, of which 186 were genotyped. In both wards, two MLVA types (MTs; MT1 and MT159) were responsible for >80% of acquisitions. Both MTs were genetically different from the probiotic E. faecium strain. Antibiotics to which ARE is resistant (hazard ratio [HR], 7.73 [95% confidence interval (CI), 4.52 to 13.22]), an ecological postantibiotic effect (HR, 7.11 [95% CI, 3.10 to 16.30]), and age (HR, 1.01 [95% CI, 0.99 to 1.02]) were associated with ARE acquisition. The HR of probiotics was 1.43 (95% CI, 0.88 to 2.34). In a setting with high selective antibiotic pressure, probiotics failed to prevent acquisition of multiresistant enterococci.
- Published
- 2010
- Full Text
- View/download PDF
35. Raloxifene and body composition and muscle strength in postmenopausal women: a randomized, double-blind, placebo-controlled trial.
- Author
-
Jacobsen DE, Samson MM, Emmelot-Vonk MH, and Verhaar HJ
- Subjects
- Aged, Aged, 80 and over, Double-Blind Method, Female, Hand Strength, Humans, Isometric Contraction drug effects, Residence Characteristics, Body Composition drug effects, Bone Density Conservation Agents administration & dosage, Muscle Strength drug effects, Osteoporosis, Postmenopausal prevention & control, Raloxifene Hydrochloride administration & dosage
- Abstract
Objective: To compare the effects of raloxifene and placebo on body composition and muscle strength., Design: Randomized, double-blind, placebo-controlled trial involving 198 healthy women aged 70 years or older conducted between July 2003 and January 2008 at the University Medical Centre, Utrecht, The Netherlands., Methods: Participants were randomly assigned to receive raloxifene 60 mg or placebo daily for 12 months. Measurements were taken at baseline, 3, 6, and 12 months, and change from baseline was calculated. Main outcome measures were body composition (bioelectrical impedance analysis), muscle strength, and muscle power (maximum voluntary isometric knee extension strength, explosive leg extensor power, and handgrip strength)., Results: At 12 months, the body composition of women taking raloxifene was significantly different from that of women taking placebo: fat-free mass (FFM) had increased by a mean of 0.83 (2.4) kg in the raloxifene group versus 0.03 (1.5) kg in the placebo group (P=0.05), and total body water had increased by a mean of 0.6 (1.8) litres in the raloxifene group versus a decrease of 0.06 (1.1) litres in the placebo group (P=0.02). Muscle strength and power were not significantly different., Conclusion: Raloxifene significantly changed body composition (increased FFM; increased water content) compared with placebo in postmenopausal women.
- Published
- 2010
- Full Text
- View/download PDF
36. Muscle strength and mobility in vitamin D-insufficient female geriatric patients: a randomized controlled trial on vitamin D and calcium supplementation.
- Author
-
Janssen HC, Samson MM, and Verhaar HJ
- Subjects
- Aged, Female, Humans, Knee Joint physiology, Locomotion physiology, Mobility Limitation, Motor Activity drug effects, Muscle Strength drug effects, Calcium therapeutic use, Dietary Supplements, Hand Strength physiology, Motor Activity physiology, Muscle Strength physiology, Vitamin D therapeutic use, Vitamin D Deficiency drug therapy, Vitamin D Deficiency epidemiology
- Abstract
Background and Aims: Insufficient vitamin D status, commonly found in older people, has been associated with muscle weakness which, in old age, impairs mobility and is a risk factor for falling. In a randomized, double-blind placebo-controlled trial, we tested the hypothesis that vitamin D + calcium supplementation improves muscle strength and mobility, compared with calcium mono-therapy in vitamin D-insufficient female geriatric patients., Methods: Seventy female geriatric patients >65 years of age with serum 25-hydroxyvitamin D3 (25OHD) concentrations between 20 and 50 nmol/L, visiting an outpatient geriatric department, were included. Participants received either cholecalciferol 400 IU/day + calcium 500 mg/day (D/Cal group) or a placebo + calcium 500 mg/day (Plac/Cal group) for 6 months. At baseline and 6 months, muscle strength, power and functional mobility were tested., Results: At baseline, 25OHD was significantly (p<0.05) associated with knee extension strength (r=0.42), handgrip strength (r=0.28), leg extension power (r=0.34), Timed Get Up and Go (r=-0.31) and Modified Cooper test (r=0.44). At 6 months, a significant difference in 25OHD (77.2 vs 41.6 nmol/L, p<0.001) and 1,25OHD was found between the two groups. Significantly improving vitamin D status in the D/Cal group compared with the Plac/Cal group did not result in a significant difference in strength or functional mobility between the two groups., Conclusions: Daily 400 IU vitamin D + 500 mg calcium supplementation is not enough to significantly improve strength or mobility in vitamin D-insufficient female geriatric patients.
- Published
- 2010
- Full Text
- View/download PDF
37. Reduction in falling after a falls-assessment.
- Author
-
Hansma AH, Emmelot-Vonk MH, and Verhaar HJ
- Subjects
- Accidental Falls statistics & numerical data, Accidents, Home prevention & control, Accidents, Home statistics & numerical data, Aged, Aged, 80 and over, Cohort Studies, Female, Follow-Up Studies, Geriatric Assessment, Geriatrics, Humans, Incidence, Male, Muscle Strength physiology, Netherlands, Postural Balance physiology, Retrospective Studies, Risk Assessment, Accidental Falls prevention & control, Patient Education as Topic methods, Primary Prevention methods
- Abstract
The aim of this single-center retrospective cohort study was to evaluate the effect of a multidisciplinary falls-assessment, consisting of identification and possible modification of risk factors for falls, on the frequency of falls among elderly individuals attending the geriatric outpatient department of the University Medical Center (UMC) Utrecht, the Netherlands. The characteristics of 70 elderly people who visited the outpatient department because of a fall in the period from May 2005 till February 2007 were evaluated. The effectiveness of the falls-assessment was evaluated by telephone interview of those individuals who had attended the falls-assessment. Fifty-three patients (mean age=79.8 years) were interviewed after a mean+/-S.D. of 1.47+/-0.41 years (ranging 0.72-2.34 years) subsequent to the falls-assessment. Falls-assessment led to significantly fewer falls, from 3.78+/-4.66 at the time of the assessment at baseline to 1.10+/-1.86 at the time of the interview (p=0.000041). Fear of falling was also significantly diminished. In conclusion, falls-assessment leads to fewer falls and less fear of falling among elderly individuals.
- Published
- 2010
- Full Text
- View/download PDF
38. Medical treatment of osteoporosis in the elderly.
- Author
-
Verhaar HJ
- Subjects
- Accidental Falls, Aged, Aged, 80 and over, Bone Density, Female, Fractures, Bone prevention & control, Humans, Male, Osteoporosis prevention & control, Parathyroid Hormone therapeutic use, Bone Density Conservation Agents therapeutic use, Osteoporosis drug therapy
- Abstract
Fractures, mostly of the hip and pelvis, wrist, and sometimes of the vertebra, account for nearly half of emergency department treatments for elderly individuals seen because of a fall. Bone density measurements show that more than half of these patients have osteoporosis. The notion that it is too late to start treatment in a late stage of the disease forms a barrier to treatment. The aim of this article is to evaluate the effectiveness of therapeutic options for osteoporosis in the elderly, with a view to reducing the incidence of fractures. Although most studies of fracture reduction with medical treatment were not designed for the "geriatric" population, the average age of participants in most clinical trials was about 70 years. Nowadays, clinicians can choose from several effective treatments for the prevention of osteoporotic fractures in high-risk postmenopausal women. Data on the antifracture potential of calcium/vitamin D, raloxifene, bisphosphonates, strontium ralenate, and parathyroid hormone are now available. In all major studies patients also received calcium and vitamin D supplements. Bisphosphonates and strontium ranelate are good choices for first- or second-line treatment, while for the time being parathyroid hormone should only be used for the second-line treatment of osteoporosis in the elderly. The ease of use of bisphosphonates, with once weekly, once monthly, or intravenous administration, may be advantageous for elderly patients already taking multiple medications.
- Published
- 2009
- Full Text
- View/download PDF
39. Low bone mineral density in adult patients with moderate to severe atopic dermatitis.
- Author
-
Haeck IM, Hamdy NA, Timmer-de Mik L, Lentjes EG, Verhaar HJ, Knol MJ, de Bruin-Weller MS, and Bruijnzeel-Koomen CA
- Subjects
- Adult, Aged, Aged, 80 and over, Bone Density physiology, Dermatitis, Atopic complications, Dose-Response Relationship, Drug, Female, Humans, Life Style, Male, Middle Aged, Osteoporosis physiopathology, Prevalence, Risk Factors, Severity of Illness Index, Surveys and Questionnaires, Young Adult, Absorptiometry, Photon methods, Adrenal Cortex Hormones adverse effects, Bone Density drug effects, Dermatitis, Atopic drug therapy, Osteoporosis chemically induced
- Abstract
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease commonly treated with topical corticosteroids. The inflammatory nature of this disorder and the use of topical corticosteroids represent potential risk factors for bone loss., Objectives: The aim was to assess the prevalence of osteoporosis and osteopenia in adult patients with moderate to severe AD. In addition, the associations between topical/oral corticosteroid use and bone mineral density (BMD) and between disease activity and BMD were studied., Patients and Methods: We studied 125 adult patients with moderate to severe AD. Using dual-energy X-ray absorptiometry, BMD was measured at lumbar spine and hips. The cumulative dose of topical and oral corticosteroids was calculated from pharmacy prescription records. Lifestyle parameters were collected by a questionnaire. Biochemical parameters of bone metabolism and disease activity [serum concentration of thymus and activation-regulated chemokine (TARC) levels] were also measured., Results: Osteoporosis was documented in six patients (4.8%) and osteopenia in 41 patients (32.8%); 30.4% of the patients had a Z-score
- Published
- 2009
- Full Text
- View/download PDF
40. Use of anti-depressants and the risk of fracture of the hip or femur.
- Author
-
van den Brand MW, Pouwels S, Samson MM, van Staa TP, Thio B, Cooper C, Leufkens HG, Egberts AC, Verhaar HJ, and de Vries F
- Subjects
- Adolescent, Adult, Aged, Antidepressive Agents administration & dosage, Antidepressive Agents, Tricyclic administration & dosage, Antidepressive Agents, Tricyclic adverse effects, Drug Administration Schedule, Epidemiologic Methods, Female, Femoral Fractures epidemiology, Hip Fractures epidemiology, Humans, Male, Middle Aged, Netherlands epidemiology, Selective Serotonin Reuptake Inhibitors administration & dosage, Selective Serotonin Reuptake Inhibitors adverse effects, Young Adult, Antidepressive Agents adverse effects, Femoral Fractures chemically induced, Hip Fractures chemically induced
- Abstract
Summary: Anti-depressants are used largely, but have serious side effects. We show that both selective serotonin re-uptake inhibitors (SSRIs) and tricyclic anti-depressants (TCAs) increase the risk of hip/femur fracture and that this risk is time related and depends on the degree of serotonin transporter inhibition. This should be considered when prescribing anti-depressants to patients., Introduction: Anti-depressants are known to have serious side effects. We examined the association between the use of anti-depressants and the risk of hip/femur fractures with a special focus on the relation with the degree of 5-hydroxytryptamine transporter (5-HTT) inhibition and the duration of use., Methods: A case-control study was conducted within the Dutch PHARMO-RLS database. Cases (n = 6,763) were adult patients with a first hip/femur fracture during the study period. For each case, four controls (n = 26341) were matched by age, gender and geographic region., Results: The risk of hip/femur fracture increased with current use of SSRIs (adjusted odds ratio (OR(adj)) 2.35 [95% confidence interval (CI) 1.94-2.84]) and TCAs (ORadj 1.76 [95% CI 1.45-2.15]). The risk of hip/femur fracture declined rapidly after discontinuation of use. The risk of hip/femur fracture increased as the degree of 5-HTT inhibition of all anti-depressants increased from OR(adj) 1.64 [95% CI 1.14-2.35] for drugs with low 5-HTT inhibition to OR(adj) 2.31 [95% CI 1.94-2.76] for those with high 5-HTT inhibiting properties., Conclusion: Current use of both SSRIs and TCAs increase hip/femur fracture risk. Further studies are needed to elucidate the mechanistic pathways and the relation with the underlying pathophysiology. Until then, the elevated fracture risk should be considered when prescribing anti-depressants.
- Published
- 2009
- Full Text
- View/download PDF
41. Spine radiographs to improve the identification of women at high risk for fractures.
- Author
-
Netelenbos JC, Lems WF, Geusens PP, Verhaar HJ, Boermans AJ, Boomsma MM, Mulder PG, and Papapoulos SE
- Subjects
- Absorptiometry, Photon, Aged, Aged, 80 and over, Bone Density, False Negative Reactions, Female, Humans, Middle Aged, Osteoporosis, Postmenopausal complications, Osteoporosis, Postmenopausal physiopathology, Patient Selection, Prospective Studies, Risk Factors, Spinal Curvatures etiology, Spinal Curvatures physiopathology, Spinal Fractures etiology, Spinal Fractures physiopathology, Osteoporosis, Postmenopausal diagnostic imaging, Spinal Curvatures diagnostic imaging, Spinal Fractures diagnostic imaging
- Abstract
Summary: In women older than 60 years with clinical risk factors for osteoporosis but without osteoporosis based on bone mineral density (T-score >or= -2.5), a systematic survey with X-rays of the spine identified previously unknown vertebral deformities in 21% of women., Introduction: This study determines the prevalence of vertebral deformities in elderly women with clinical risk factors for osteoporosis but with BMD values above the threshold for osteoporosis (T-score >or= -2.5)., Methods: Bisphosphonate naïve women older than 60 years attending 35 general practices in the Netherlands with >or=2 clinical risk factors for osteoporosis were invited for BMD measurement (DXA). In women with T-score >or= -2.5 at both spine and the hips, lateral radiographs of the thoracic and lumbar spine were performed., Results: Of 631 women with a DXA measurement, 187 (30%) had osteoporosis (T-score < -2.5 at the spine or the hip). Of the remaining 444 women with T-score >or= -2.5 at both spine and hip, 387 had additional spine radiographs, of whom 80 (21%) had at least one vertebral deformity., Conclusion: In elderly women with clinical risk factors for osteoporosis but BMD T-score >or= -2.5, addition of spine radiographs identified vertebral deformities in 21% (95% CI: 17-25). Since these women are at risk of future fractures, antiosteoporotic treatment should be considered.
- Published
- 2009
- Full Text
- View/download PDF
42. Predicting osteoporosis in patients with a low-energy fracture.
- Author
-
Timmer MH, Samson MM, Monninkhof EM, De Ree B, and Verhaar HJ
- Subjects
- Accidental Falls statistics & numerical data, Aged, Bone Density, Cross-Sectional Studies, Female, Humans, Male, Prospective Studies, Risk Factors, Surveys and Questionnaires, Fractures, Bone epidemiology, Osteoporosis diagnosis, Osteoporosis epidemiology
- Abstract
The multicenter cross-sectional study was designed to develop a simple rule to predict the risk of osteoporosis in the patients with a low-energy fracture (LEF). Furthermore, we aimed to investigate the incidence of fall-related risk factors. We included 206 patients with age over 50 and an LEF at the emergency room. All patients underwent osteoporosis and fall risk assessment and dual-energy X-ray absorptiometry (DEXA) of both hips and the lumbar spine. The incidence of osteoporosis in our study population was 41% (84 cases of 206). Fifty-four percent of the patients reported at least one fall-related risk factor. Mobility problems occurred in 31% and osteoarthritis in 19%. The final osteoporosis prediction rule included age, positive family history, immobility, and low-body weight. The discrimination of the rule after correction for over-optimism was good (receiver operating curve (ROC)=ROC area=0.79). This simple rule may be helpful to select patients who need further osteoporosis assessment.
- Published
- 2009
- Full Text
- View/download PDF
43. Frailty: defining and measuring of a concept.
- Author
-
Pel-Littel RE, Schuurmans MJ, Emmelot-Vonk MH, and Verhaar HJ
- Subjects
- Activities of Daily Living, Aged, Cognition, Diagnosis, Humans, Mobility Limitation, Nutritional Status, Aging physiology, Frail Elderly, Geriatric Assessment methods
- Abstract
Older, more vulnerable individuals are increasingly often described in the literature as being frail. Because frailty is often perceived as being undesirable and associated with high health risks, it is important to establish how we can predict, recognize, and treat frailty. Frailty is predisposed by advancing age in combination with physiological deterioration, especially a loss of muscle mass and bone density. Although the symptoms of frailty are diverse, the most common symptoms are a deterioration of activities of daily living (ADL), mobility, nutritional status, cognition, and endurance. The consequences of frailty are institutionalization, morbidity, and mortality. The main determinants of frailty are limitations in ADL, weight loss, diminished mobility or patterns of activity, lowered serum cholesterol level, and sensitivity to change. There is no gold standard for the measurement of frailty, and often studies use a combination of instruments. Although a couple of multidimensional instruments have been developed to measure frailty in its totality, the reliability and validity of these instruments have yet to be established. Successful interventions against frailty include increasing muscle strength through training and individualized recommendations made on the basis of an extensive geriatric assessment.
- Published
- 2009
- Full Text
- View/download PDF
44. Effect of testosterone supplementation on sexual functioning in aging men: a 6-month randomized controlled trial.
- Author
-
Emmelot-Vonk MH, Verhaar HJ, Nakhai-Pour HR, Grobbee DE, and van der Schouw YT
- Subjects
- Aged, Aged, 80 and over, Double-Blind Method, Humans, Logistic Models, Male, Middle Aged, Odds Ratio, Sexual Behavior, Surveys and Questionnaires, Testosterone therapeutic use, Aging psychology, Sexuality drug effects, Testosterone analogs & derivatives
- Abstract
Serum testosterone levels decline significantly with aging and this has been associated with reduced sexual function. We have conducted a double-blind, randomized, placebo-controlled trial to investigate the effect of testosterone supplementation on sexual function in 237 elderly men with a testosterone level <13.7 nmol l(-1). Participants were randomly assigned to receive oral testosterone undecanoate or a placebo for 6 months. A total of 207 men completed the study. After treatment, there were no differences in scores on sexual function between the groups. Subanalysis showed that although a baseline testosterone level in the lowest tertile was associated with significantly lower scores for sexual fantasies, desire of sexual contact and frequency of sexual contact, supplementation of testosterone did not result in improvement on any of these items in this group. In conclusion, the findings do not support the view that testosterone undecanoate supplementation for 6 months to elderly men with low-normal testosterone concentrations favorably affects sexual function.
- Published
- 2009
- Full Text
- View/download PDF
45. Frequency and outcome of pulmonary polymethylmethacrylate embolism during percutaneous vertebroplasty.
- Author
-
Venmans A, Lohle PN, van Rooij WJ, Verhaar HJ, and Mali WP
- Subjects
- Aged, Aged, 80 and over, Bone Cements therapeutic use, Female, Humans, Incidence, Male, Middle Aged, Netherlands epidemiology, Risk Factors, Treatment Outcome, Fractures, Compression epidemiology, Fractures, Compression therapy, Polymethyl Methacrylate therapeutic use, Pulmonary Embolism epidemiology, Risk Assessment methods, Spinal Fractures epidemiology, Spinal Fractures therapy, Vertebroplasty statistics & numerical data
- Abstract
Background and Purpose: During percutaneous polymethylmethacrylate (PMMA) vertebroplasty (PV), PMMA cement may migrate into the venous system and subsequently be transported to the pulmonary arteries. Frequency, outcome, and imaging findings of PMMA pulmonary embolism are poorly understood. We retrospectively assessed the frequency and outcome of PMMA embolism during PV in a large patient cohort and evaluated the relationship of the volume of injected PMMA to the occurrence of pulmonary PMMA embolism., Materials and Methods: Between 2001 and 2007, 532 osteoporotic compression fractures in 299 consecutive patients were treated with PV. PMMA embolism was defined as venous PMMA migration toward the lungs visible on biplane fluoroscopy during PV. CT was performed immediately and 1 year after PMMA migration., Results: Venous PMMA migration occurred during 11 PVs in 11 patients (2.1%, 95% confidence interval, 1.1-3.7%). CT in 8 patients demonstrated small peripheral pulmonary PMMA emboli. All 11 patients remained asymptomatic during 1-year follow-up. Repeat CT scanning after 1 year in 6 patients demonstrated unchanged pulmonary PMMA deposits without late reactive changes. Mean injected cement volume in patients with and without PMMA embolism was not different (3.6 +/- 1.06 mL versus 3.3 +/- 1.16 mL, P = .43). Similar comparison for thoracic and thoracolumbar vertebrae yielded P values of .07 and .9., Conclusion: Pulmonary PMMA embolism during PV is an infrequent complication without permanent clinical sequelae. After 1 year, no pulmonary reaction was seen on CT. No definite relationship of PMMA emboli with injected cement volume could be established.
- Published
- 2008
- Full Text
- View/download PDF
46. [Treatment of osteoporosis in the elderly: what is the evidence?].
- Author
-
Verhaar HJ
- Subjects
- Age Factors, Aged, Aged, 80 and over, Alendronate therapeutic use, Etidronic Acid analogs & derivatives, Etidronic Acid therapeutic use, Evidence-Based Medicine, Female, Fractures, Bone etiology, Humans, Male, Osteoporosis prevention & control, Osteoporosis, Postmenopausal drug therapy, Osteoporosis, Postmenopausal prevention & control, Raloxifene Hydrochloride therapeutic use, Risedronic Acid, Teriparatide therapeutic use, Treatment Outcome, Aging physiology, Bone Density drug effects, Bone Density Conservation Agents therapeutic use, Fractures, Bone prevention & control, Osteoporosis drug therapy
- Abstract
Many older people, especially women, and their doctors still see osteoporosis as part of the natural course of ageing instead of as a preventable or treatable disorder. Height loss, hyperkyphosis, back pain, and fractures are accepted as consequences of ageing. The notion that it is too late to start treatment in a late stage of the disease forms another barrier to treatment. Although most studies of fracture reduction with medical treatment were not designed for the "geriatric" population, the average age of participants in most clinical trials was about 70 years. In all major studies patients also received calcium and vitamin D supplements. Nowadays, clinicians can choose from several effective treatments for the prevention of osteoporotic fractures in high-risk postmenopausal women. Data on the anti-fracture potential of calcium/vitamin D, raloxifene, bisphosphonates, strontium ralenate, and parathyroid hormone are now available. Bisphosphonates and strontium ralenate are good choices for first- or second-line treatment, while for the time being parathyroid hormone should only be used for the second-line treatment of osteoporosis in the elderly.
- Published
- 2008
- Full Text
- View/download PDF
47. [PTH analogues: comparable or different?].
- Author
-
Verhaar HJ and Lems WF
- Subjects
- Aged, Aged, 80 and over, Female, Fractures, Bone epidemiology, Humans, Male, Parathyroid Hormone analogs & derivatives, Risk Factors, Treatment Outcome, Bone Density Conservation Agents therapeutic use, Fractures, Bone prevention & control, Osteoporosis drug therapy, Parathyroid Hormone therapeutic use, Teriparatide therapeutic use
- Published
- 2008
- Full Text
- View/download PDF
48. Physical activity and enhanced fitness to improve cognitive function in older people without known cognitive impairment.
- Author
-
Angevaren M, Aufdemkampe G, Verhaar HJ, Aleman A, and Vanhees L
- Subjects
- Aged, Cognition Disorders prevention & control, Humans, Memory physiology, Middle Aged, Oxygen Consumption physiology, Randomized Controlled Trials as Topic, Cognition physiology, Exercise physiology, Physical Fitness physiology
- Abstract
Background: Physical activity is beneficial for healthy ageing. It may also help maintain good cognitive function in older age. Aerobic activity improves cardiovascular fitness, but it is not known whether this sort of fitness is necessary for improved cognitive function. Studies in which activity, fitness and cognition are reported in the same individuals could help to resolve this question., Objectives: To assess the effectiveness of physical activity, aimed at improving cardiorespiratory fitness, on cognitive function in older people without known cognitive impairment., Search Strategy: We searched MEDLINE, EMBASE, PEDro, SPORTDiscus, PsycINFO, CINAHL, Cochrane Controlled Trials Register (CENTRAL), Dissertation abstracts international and ongoing trials registers on 15 December 2005 with no language restrictions., Selection Criteria: All published randomised controlled trials comparing aerobic physical activity programmes with any other intervention or no intervention with participants older than 55 years of age were eligible for inclusion., Data Collection and Analysis: Eleven RCTs fulfilling the inclusion criteria are included in this review. Two reviewers independently extracted the data from these included studies., Main Results: Eight out of 11 studies reported that aerobic exercise interventions resulted in increased cardiorespiratory fitness of the intervention group (an improvement on the maximum oxygen uptake test which is considered to be the single best indicator of the cardiorespiratory system) of approximately 14% and this improvement coincided with improvements in cognitive capacity. The largest effects on cognitive function were found on motor function and auditory attention (effect sizes of 1.17 and 0.50 respectively). Moderate effects were observed for cognitive speed (speed at which information is processed; effect size 0.26) and visual attention (effect size 0.26)., Authors' Conclusions: There is evidence that aerobic physical activities which improve cardiorespiratory fitness are beneficial for cognitive function in healthy older adults, with effects observed for motor function, cognitive speed, auditory and visual attention. However, the majority of comparisons yielded no significant results. The data are insufficient to show that the improvements in cognitive function which can be attributed to physical exercise are due to improvements in cardiovascular fitness, although the temporal association suggests that this might be the case. Larger studies are still required to confirm whether the aerobic training component is necessary, or whether the same can be achieved with any type of physical exercise. At the same time, it would be informative to understand why some cognitive functions seem to improve with (aerobic) physical exercise while other functions seem to be insensitive to physical exercise. Clinicians and scientists in the field of neuropsychology should seek mutual agreement on a smaller battery of cognitive tests to use, in order to render research on cognition clinically relevant and transparent and heighten the reproducibility of results for future research.
- Published
- 2008
- Full Text
- View/download PDF
49. Intensity, but not duration, of physical activities is related to cognitive function.
- Author
-
Angevaren M, Vanhees L, Wendel-Vos W, Verhaar HJ, Aufdemkampe G, Aleman A, and Verschuren WM
- Subjects
- Adult, Age Factors, Cardiovascular Diseases epidemiology, Cardiovascular Diseases psychology, Cross-Sectional Studies, Female, Follow-Up Studies, Humans, Incidence, Luria-Nebraska Neuropsychological Battery, Male, Middle Aged, Netherlands epidemiology, Retrospective Studies, Sex Factors, Surveys and Questionnaires, Cognition physiology, Motor Activity physiology
- Abstract
Background: Physical activity is thought to facilitate cognitive performance and to slow down the rate of age-related cognitive decline. This study aimed to investigate the association between the time spent on physical activity as well as the average intensity of these activities and cognitive function., Design: Cross-sectional analysis., Methods: Our study population comprised of 1927 healthy men and women aged 45-70 years in the Netherlands, examined from 1995 until 2000. Physical activity was assessed with an extensive questionnaire, and cognitive function by a neuropsychological test battery., Results: Multivariate linear regression analysis showed that intensity of weekly physical activities is significantly positively associated with processing speed, memory, mental flexibility and overall cognitive function. No significant associations were observed between the time spent weekly on physical activities and the various cognitive domains. At the same time, variation in activities was significantly positively associated with speed, memory, mental flexibility and overall cognitive function., Conclusions: Average intensity of weekly physical activities and variation in activities are positively and significantly associated with cognitive performance on processing speed, memory and mental flexibility as well as performance on overall cognitive function.
- Published
- 2007
- Full Text
- View/download PDF
50. Oral testosterone supplementation and chronic low-grade inflammation in elderly men: a 26-week randomized, placebo-controlled trial.
- Author
-
Nakhai-Pour HR, Grobbee DE, Emmelot-Vonk MH, Bots ML, Verhaar HJ, and van der Schouw YT
- Subjects
- Administration, Oral, Aged, Aged, 80 and over, C-Reactive Protein drug effects, Double-Blind Method, Humans, Inflammation blood, Male, Middle Aged, Testosterone blood, Testosterone pharmacology, Testosterone therapeutic use, C-Reactive Protein metabolism, Inflammation drug therapy, Testosterone analogs & derivatives
- Abstract
Background: To determine the effect of oral testosterone supplementation on systemic low-grade inflammation measured by high-sensitive C-reactive protein (hs-CRP) in aging men with low testosterone levels., Methods: Two hundred thirty-seven men aged 60 to 80 years with a testosterone level of <13.7 nmol/L (below the 50th percentile of the population distribution) were recruited into a double-blind randomized placebo-controlled trial. Participants were randomized to either 4 capsules of 40 mg testosterone undecanoate (Andriol Testocaps, NV Organon, Oss, The Netherlands) or placebo daily for 26 weeks. Serum levels of hs-CRP were measured at baseline and at 26 weeks using a near-infrared particle immunoassay of the Synchron LX System (Beckman Coulter, Fullteron, CA)., Results: The median baseline hs-CRP level was 1.95 mg/L (0.30-6.43) in the testosterone group compared with 1.90 mg/L (0.40-5.91) in the placebo group. After 26 weeks of testosterone supplementation therapy, the 2 intervention groups were not statistically significantly different (median hs-CRP 2.20 vs 2.00 mg/L, interquartile range 0.40-6.54 vs 0.50-5.70, P = .36). In subgroup analysis, neither baseline testosterone level, nor age, nor baseline CRP-level modified the effect of testosterone supplementation on CRP levels., Conclusion: Oral testosterone undecanoate supplementation, in dosage of 160 mg daily for 26 weeks, does not increase hs-CRP levels in elderly men.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.